切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (06) : 326 -330. doi: 10.3877/cma.j.issn.1674-0807.2019.06.002

所属专题: 文献

论著

microRNA-34c-3p在浸润性乳腺癌中的表达及其与BRCA基因的关系
巫姜1, 石文龙1, 孟庆杰1, 赵戈1, 樊菁1, 王廷1, 李南林1, 凌瑞1,()   
  1. 1. 710032 西安,空军军医大学西京医院甲乳血管外科
  • 收稿日期:2017-12-25 出版日期:2019-12-01
  • 通信作者: 凌瑞
  • 基金资助:
    国家自然科学基金资助项目(81472598)

Expression of microRNA-34c-3p in invasive breast cancer and correlation with BRCA gene

Jiang Wu1, Wenlong Shi1, Qingjie Meng1, Ge Zhao1, Jing Fan1, Ting Wang1, Nanlin Li1, Rui Ling1,()   

  1. 1. Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, Xi’an 710032, China
  • Received:2017-12-25 Published:2019-12-01
  • Corresponding author: Rui Ling
  • About author:
    Corresponding author: Ling Rui, Email:
引用本文:

巫姜, 石文龙, 孟庆杰, 赵戈, 樊菁, 王廷, 李南林, 凌瑞. microRNA-34c-3p在浸润性乳腺癌中的表达及其与BRCA基因的关系[J/OL]. 中华乳腺病杂志(电子版), 2019, 13(06): 326-330.

Jiang Wu, Wenlong Shi, Qingjie Meng, Ge Zhao, Jing Fan, Ting Wang, Nanlin Li, Rui Ling. Expression of microRNA-34c-3p in invasive breast cancer and correlation with BRCA gene[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2019, 13(06): 326-330.

目的

分析浸润性乳腺癌microRNA-34c-3p(miR-34c-3p)的表达及其与BRCA基因突变的相关性。

方法

选取2015年2月至2017年6月在空军医科大学西京医院初次就诊的患者作为研究对象进行前瞻性研究。根据纳入条件,将患者分为浸润性乳腺癌组(55例)、乳腺癌前病变组(46例)和正常对照组(50例),分别检测miR-34c-3p在各组组织标本和血液标本中的表达水平。采用单因素方差分析比较3组间miR-34c-3p表达水平的差异,组间两两比较采用LSD法;并用Spearman秩相关分析法分析浸润性乳腺癌组织标本和血液标本中miR-34c-3p表达水平与BRCA基因突变的相关性。

结果

(1)在乳腺组织标本中,浸润性乳腺癌组、乳腺癌前病变组、正常对照组miR-34c-3p表达水平分别为0.76±0.29、1.24±0.33和1.62±0.36,3组比较,差异有统计学意义(F=27.373,P=0.020),其中,浸润性乳腺癌组miR-34c-3p表达水平明显低于乳腺癌前病变组和正常对照组(P=0.024、0.001),乳腺癌前病变组与正常对照组比较,差异无统计学意义(P=0.065)。(2)在血液标本中,浸润性乳腺癌组、乳腺癌前病变组、正常对照组miR-34c-3p表达水平分别为0.32±0.18、0.71±0.23和0.93±0.27,3组比较,差异有统计学意义(F=29.534,P=0.018),其中,浸润性乳腺癌组miR-34c-3p表达水平明显低于正常对照组(P=0.006),但浸润性乳腺癌组与乳腺癌前病变组比较、乳腺癌前病变组与正常对照组比较,miR-34c-3p表达水平的差异均无统计学意义(P=0.076、0.102)。(3)miR-34c-3p在乳腺癌组织中的表达水平与BRCA基因突变风险呈负相关(r=-0.548,P<0.001);血液标本中,miR-34c-3p表达水平与BRCA基因突变风险也呈负相关(r=-0.312,P=0.006)。

结论

miR-34c-3p在浸润性乳腺癌组织中低表达,且与BRCA基因突变存在一定的联系。

Objective

To analyze the correlation between microRNA-34c-3p (miR-34c-3p) expression and BRCA gene mutation in invasive breast cancer.

Methods

The patients treated in the Xijing Hospital, Air Force Medical University from February 2015 to June 2017 were continuously enrolled for a prospective study. The subjects were divided into the invasive breast cancer group (group A, 55 cases), the precancerous lesion group (group B, 46 cases) and the normal control group (group C, 50 cases) according to the criteria of inclusion. The expression of miR-34c-3p was detected in all tissue and blood samples. The expression of miR-34c-3p was compared among three groups using one-way analysis of variance, and pairwise comparison was performed using the LSD method. Spearman rank correlation was used to analyze the correlation between miR-34c-3p expression in invasive breast cancer tissue and blood samples and BRCA gene.

Results

(1) In the breast tissue samples, the expression of miR-34c-3p was 0.76±0.29, 1.24±0.33 and 1.62±0.36 in group A, B and C, respectively, indicating a significant difference among three groups(F=27.373, P=0.020). The miR-34c-3p expression in group A was significantly lower than that in group B or C (P= 0.024, 0.001). There was no significant difference between group B and group C (P= 0.065). (2) In the blood samples, the expression of miR-34c-3p was 0.32±0.18, 0.71±0.23 and 0.93±0.27 in group A, B and C, respectively, indicating a significant difference among three groups (F=29.534, P=0.018). The expression of miR-34c-3p in group A was significantly lower than that in group C (P=0.006). But there was no significant difference between group A and B, between group B and group C (P=0.076, 0.102). (3) The expression of miR-34c-3p was negatively correlated with the risk of BRCA gene mutation in breast cancer tissue (r=-0.548, P<0.001) and in blood samples (r=-0.312, P=0.006).

Conclusion

The low expression of miR-34c-3p is observed in invasive breast cancer tissues, which is associated with BRCA gene mutation.

表1 real-time RT-PCR引物序列
图1 采用real-time RT-PCR检测各组织标本中miR-34c-3p的表达水平
图2 采用real-time RT-PCR检测各组血液标本中miR-34c-3p的表达水平
表2 55例乳腺癌患者BRCA基因突变与癌组织miR-34c-3p表达的关系
表3 55例乳腺癌患者BRCA基因突变与血液标本中miR-34c-3p表达的关系
[1]
曹明丽. 基于分子分型的乳腺癌流行病学新认识[J]. 中国肿瘤临床,2017, 44(9): 449-451.
[2]
Chen W, Zheng R, Baade PD, et al. Cancer statitics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3]
Liu X, Feng J, Tang L, et al. The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer[J]. Int J Mol Sci, 2015, 16(2):3148-3162.
[4]
Yu Z, Kim J, He L, et al. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer[J].Biol Reprod, 2014, 91(5):113.
[5]
Yang S, Li WS, Dong F, et al. KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells[J]. J Cell Mol Med, 2014, 18(10):2092-2102.
[6]
Wang AM, Huang TT, Hsu KW, et al. Yin Yang 1 is a target of micro RNA-34 family and contributes to gastric carcinogenesis[J]. Oncotarget, 2014, 5(13): 5002-5016.
[7]
Yao L, Sun J, Zhang J, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations[J]. Breast Cancer Res Treat, 2016, 156(3): 441-445.
[8]
何松哲,何慧,陈懿,等. 不同保存和处理方式对全血标本总RNA提取的影响[J]. 中国微生态学杂志,2015, 27(2): 223-226.
[9]
Dong YS, Hou WG, Li Y, et al. Unexpected requirement for a binding partner of the syntaxin family in phagocytosis by murine testicular Sertoli cells[J].Cell Death Differ, 2016,23(5):787-800.
[10]
《BRCA数据解读中国专家共识》编写组. BRCA数据解读中国专家共识[J]. 中华病理学杂志,2017, 46(5): 293-297.
[11]
高宁,夏鹰,金虎,等. miR-34c-3p调控脑胶质瘤细胞增殖、分化、凋亡的机制研究[J]. 中国地方病防治杂志,2016, 31(12): 1386-1387.
[12]
Wu Z, Wu Y, Tian Y, et al. Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells[J]. Oncol Lett, 2013, 6(5): 1447-1452.
[13]
Xiao CZ, Wei W, Guo ZX, et al. MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression[J]. J Cancer Res Clin Onco, 2017, 143(2): 263-273.
[14]
Zhou YL, Xu YJ, Qiao CW. MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway[J]. Int J Clin Exp Pathol, 2015, 8(6): 6312-6322.
[15]
Wu J, Li WZ, Huang ML,et al. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells[J]. Biochem Biophys Res Commun, 2017, 483(1):10-16.
[16]
杨晓晨,胡震,吴炅,等. 中国汉族人群中BRCA1和BRCA2基因突变携带者患乳腺癌风险的研究[J].中国癌症杂志,2015, 25(4): 247-252.
[17]
de Juan Jiménez I, Esteban Cardeñosa E, Palanca Suela S, et al. Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population[J]. Fam Cancer, 2012, 11(1):49-56.
[18]
Bougie O, Weberpals JI. Clinical considerations of BRCA1-and BRCA2-mutation carriers: a review[J]. Int J Surg Oncol,2011, 2011:374 012.
[19]
刘伟玲,董兵,郭永军.BRCA突变型乳腺癌的靶向治疗研究进展[J].肿瘤防治研究,2017,44(1):75-78.
[20]
刘伟玲,郭永军. 乳腺癌中BRCA通路相关基因的研究进展[J]. 河南医学研究,2017, 26(1): 54-56.
[21]
杨柳春,刘晓静,靳彦文,等. 140例中国遗传高风险乳腺癌患者BRCA1和BRCA2基因突变研究[J/CD]. 中华乳腺病杂志(电子版), 2017, 11(2): 69-73.
[22]
李铁灵,郭海峰,李华洋. 三阴性年轻乳腺癌患者BRCA1、TopoⅡα、Bcl-2表达和预后的关系[J]. 现代肿瘤医学,2016,24(2): 231-233.
[23]
李海,车婧,吴懿,等. 微小RNA参与调控乳腺癌肿瘤相关巨噬细胞分化及功能的作用机制[J]. 中华实验外科杂志,2016, 33(4): 929-932.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要